Literature DB >> 11034389

Conformational epitopes on the diabetes autoantigen GAD65 identified by peptide phage display and molecular modeling.

M A Myers1, J M Davies, J C Tong, J Whisstock, M Scealy, I R Mackay, M J Rowley.   

Abstract

The major diabetes autoantigen, glutamic acid decarboxylase (GAD65), contains a region of sequence similarity, including six identical residues PEVKEK, to the P2C protein of coxsackie B virus, suggesting that cross-reactivity between coxsackie B virus and GAD65 can initiate autoimmune diabetes. We used the human islet cell mAbs MICA3 and MICA4 to identify the Ab epitopes of GAD65 by screening phage-displayed random peptide libraries. The identified peptide sequences could be mapped to a homology model of the pyridoxal phosphate (PLP) binding domain of GAD65. For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the C terminus of GAD65 that has previously been identified as critical for MICA3 binding. To confirm that the loop containing the PEVKEK sequence contributes to the MICA3 epitope, this loop was deleted by mutagenesis. This reduced binding of MICA3 by 70%. Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing amino acids, and the surface of the GAD65 PLP-binding domain surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids. Also, the two phage most reactive with MICA4 encoded the motif VALxG, and the reverse of this sequence, LAV, was located in this same region. Thus, we have defined the MICA3 and MICA4 epitopes on GAD65 using the combination of phage display, molecular modeling, and mutagenesis and have provided compelling evidence for the involvement of the PEVKEK loop in the MICA3 epitope.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034389     DOI: 10.4049/jimmunol.165.7.3830

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasis.

Authors:  Itamar Kass; David E Hoke; Mauricio G S Costa; Cyril F Reboul; Benjamin T Porebski; Nathan P Cowieson; Hervé Leh; Eugenia Pennacchietti; Julia McCoey; Oded Kleifeld; Carla Borri Voltattorni; David Langley; Brendan Roome; Ian R Mackay; Daniel Christ; David Perahia; Malcolm Buckle; Alessandro Paiardini; Daniela De Biase; Ashley M Buckle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

2.  Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis.

Authors:  T A M A Al-Bukhari; P M Radford; G Bouras; C Davenport; S M Trigwell; G-F Bottazzo; M Lai; H L Schwartz; P J Tighe; I Todd
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

3.  [From the allergen-recognition by antibodies to new therapeutic concepts].

Authors:  Brigitte Hantusch; Erika Jensen-Jarolim
Journal:  Wien Med Wochenschr       Date:  2008

4.  Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient.

Authors:  J P Banga; J K Moore; N Duhindan; A M Madec; P M van Endert; J Orgiazzi; J Endl
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides.

Authors:  Natalia Tarnovitski; Leslie J Matthews; Jianhua Sui; Jonathan M Gershoni; Wayne A Marasco
Journal:  J Mol Biol       Date:  2006-03-22       Impact factor: 5.469

6.  Mapping of human autoantibody binding sites on the calcium-sensing receptor.

Authors:  E Helen Kemp; Nikos G Gavalas; Samia Akhtar; Kai J E Krohn; J Carl Pallais; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.